$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000162828020015769 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$78.32M	$74.57M	$62.90M
YoY Change	24.52%	22.55%	91.36%
Cost Of Revenue	$28.41M	$21.19M	$21.84M
YoY Change	30.08%	14.48%	56.56%
Gross Profit	$49.91M	$53.38M	$41.06M
YoY Change	21.55%	26.1%	116.9%
Gross Profit Margin	63.73%	71.58%	65.28%
Selling, General & Admin	$100.8M	$91.39M	$41.15M
YoY Change	144.93%	159.32%	38.74%
% of Gross Profit	201.94%	171.2%	100.22%
Research & Development	$40.28M	$36.25M	$25.88M
YoY Change	55.64%	47.52%	55.44%
% of Gross Profit	80.71%	67.9%	63.03%
Depreciation & Amortization	$4.610M	$3.800M	$3.450M
YoY Change	33.62%	52.0%	-43.44%
% of Gross Profit	9.24%	7.12%	8.4%
Operating Expenses	$141.1M	$127.6M	$67.02M
YoY Change	110.49%	113.4%	44.72%
Operating Profit	-$91.16M	-$74.25M	-$25.96M
YoY Change	251.16%	324.86%	-5.19%
Interest Expense	-$3.040M	$8.000K	-$231.5M
YoY Change	-98.69%	-97.14%	-10432.59%
% of Operating Profit
Other Income/Expense, Net	$1.420M	$345.0K	$234.8M
YoY Change	-99.4%	92.74%	-261000.0%
Pretax Income	-$92.78M	-$71.60M	-$22.60M
YoY Change	310.53%	438.68%	-10.46%
Income Tax	$260.0K	$68.00K	-$490.0K
% Of Pretax Income
Net Earnings	-$93.75M	-$71.67M	-$25.21M
YoY Change	271.88%	447.52%	0.36%
Net Earnings / Revenue	-119.7%	-96.11%	-40.08%
Basic Earnings Per Share		-$0.78
Diluted Earnings Per Share	-$937.1K	-$0.78	-$268.1K
COMMON SHARES
Basic Shares Outstanding	99.97M shares	99.55M shares	93.91M shares
Diluted Shares Outstanding		99.55M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.795B	$1.013B	$522.8M
YoY Change	243.32%	93.77%	24.77%
Cash & Equivalents	$833.0M	$142.9M	$143.2M
Short-Term Investments	$961.9M	$870.5M	$379.6M
Other Short-Term Assets	$17.50M	$9.900M	$11.40M
YoY Change	53.51%	73.68%	119.23%
Inventory	$22.72M	$27.73M	$15.18M
Prepaid Expenses
Receivables	$53.30M	$36.26M	$47.99M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.888B	$1.087B	$597.4M
YoY Change	216.12%	86.48%	27.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.78M	$61.88M	$43.67M
YoY Change	43.77%	51.82%	40.85%
Goodwill	$3.290M	$3.290M	$3.290M
YoY Change	0.0%	12.36%
Intangibles	$16.16M	$16.65M	$8.524M
YoY Change	89.52%	90.12%
Long-Term Investments	$246.6M	$51.40M	$268.8M
YoY Change	-8.26%	-83.01%	246.39%
Other Assets	$17.25M	$5.453M	$4.882M
YoY Change	253.4%	77.45%	138.61%
Total Long-Term Assets	$383.4M	$174.8M	$365.2M
YoY Change	5.0%	-52.14%	208.4%
TOTAL ASSETS
Total Short-Term Assets	$1.888B	$1.087B	$597.4M
Total Long-Term Assets	$383.4M	$174.8M	$365.2M
Total Assets	$2.272B	$1.262B	$962.5M
YoY Change	136.02%	33.09%	63.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.340M	$18.28M	$16.20M
YoY Change	-54.68%	51.66%	52.2%
Accrued Expenses	$22.64M	$22.31M	$25.70M
YoY Change	-11.92%	29.43%	258.08%
Deferred Revenue	$8.550M	$7.337M	$12.28M
YoY Change	-30.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$66.81M	$71.97M	$72.73M
YoY Change	-8.15%	6.12%	54.94%
LONG-TERM LIABILITIES
Long-Term Debt	$806.3M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$1.520M	$1.856M	$1.672M
YoY Change	-9.09%	52.13%	414.46%
Total Long-Term Liabilities	$1.520M	$1.856M	$1.672M
YoY Change	-9.09%	52.13%	414.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.81M	$71.97M	$72.73M
Total Long-Term Liabilities	$1.520M	$1.856M	$1.672M
Total Liabilities	$916.2M	$113.5M	$114.5M
YoY Change	699.87%	31.31%	83.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$606.6M	-$512.8M	-$352.8M
YoY Change	71.93%	56.55%	25.64%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.298B	$1.092B	$798.4M
YoY Change
Total Liabilities & Shareholders Equity	$2.272B	$1.262B	$962.5M
YoY Change	136.02%	33.09%	63.86%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	-$93.75M	-$71.67M	-$25.21M
YoY Change	271.88%	447.52%	0.36%
Depreciation, Depletion And Amortization	$4.610M	$3.800M	$3.450M
YoY Change	33.62%	52.0%	-43.44%
Cash From Operating Activities	-$59.23M	-$8.050M	-$30.34M
YoY Change	95.22%	-696.3%	14.32%
INVESTING ACTIVITIES
Capital Expenditures	-$7.280M	-$9.790M	-$7.020M
YoY Change	3.7%	15.86%	139.59%
Acquisitions
YoY Change
Other Investing Activities	-$290.4M	-$4.870M	$30.38M
YoY Change	-1055.92%	-82.15%	-115.6%
Cash From Investing Activities	-$297.7M	-$14.65M	$23.36M
YoY Change	-1374.36%	-59.0%	-111.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.047B	790.0K	3.070M
YoY Change	33995.44%	-88.5%	-98.77%
NET CHANGE
Cash From Operating Activities	-59.23M	-8.050M	-30.34M
Cash From Investing Activities	-297.7M	-14.65M	23.36M
Cash From Financing Activities	1.047B	790.0K	3.070M
Net Change In Cash	689.8M	-21.91M	-3.910M
YoY Change	-17742.2%	-20.36%	-114.96%
FREE CASH FLOW
Cash From Operating Activities	-$59.23M	-$8.050M	-$30.34M
Capital Expenditures	-$7.280M	-$9.790M	-$7.020M
Free Cash Flow	-$51.95M	$1.740M	-$23.32M
YoY Change	122.77%	-82.24%	-1.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38683
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 Penobscot Dr.
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	855
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99972386	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142945000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143228000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	870459000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	379574000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36255000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47986000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	27731000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	15181000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9898000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11389000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	1087288000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	597358000	USD
CY2020Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	51398000	USD
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	268783000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	61882000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43668000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36103000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29140000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16645000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8524000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q3	gh	Capitalized License Fees CapitalizedLicenseFees	50000	USD
CY2019Q4	gh	Capitalized License Fees CapitalizedLicenseFees	6890000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5453000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4882000	USD
CY2020Q3	us-gaap	Assets Assets	1262109000	USD
CY2019Q4	us-gaap	Assets Assets	962535000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	18281000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16197000	USD
CY2020Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	24037000	USD
CY2019Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	18557000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22312000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25703000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7337000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12277000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	71967000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72734000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39682000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33256000	USD
CY2020Q3	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	0	USD
CY2019Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	6880000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1856000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1672000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	113505000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	114542000	USD
CY2020Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	56400000	USD
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	49600000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99897188	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99897188	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94261414	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94261414	shares
CY2020Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1601188000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1150090000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3862000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1111000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-512847000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-352809000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1092204000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798393000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1262109000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	962535000	USD
CY2020Q3	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	60384000	USD
CY2019Q3	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	52147000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	171621000	USD
	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	123048000	USD
CY2020Q3	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	14185000	USD
CY2019Q3	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	8701000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	36793000	USD
	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	28430000	USD
CY2020Q3	us-gaap	Revenues Revenues	74569000	USD
CY2019Q3	us-gaap	Revenues Revenues	60848000	USD
	us-gaap	Revenues Revenues	208414000	USD
	us-gaap	Revenues Revenues	151478000	USD
CY2020Q3	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	16699000	USD
CY2019Q3	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	16578000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	52699000	USD
	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	42251000	USD
CY2020Q3	gh	Costof Development Services CostofDevelopmentServices	4488000	USD
CY2019Q3	gh	Costof Development Services CostofDevelopmentServices	1936000	USD
	gh	Costof Development Services CostofDevelopmentServices	11429000	USD
	gh	Costof Development Services CostofDevelopmentServices	6631000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36245000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24569000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109580000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60417000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25095000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18802000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	75225000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	56048000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66294000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16440000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	123265000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42540000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	148821000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	78325000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	372198000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	207887000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-74252000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17477000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-163784000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56409000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2313000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4286000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8271000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9870000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	8000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	280000	USD
	us-gaap	Interest Expense InterestExpense	30000	USD
	us-gaap	Interest Expense InterestExpense	860000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	345000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	179000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2421000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	275000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-71602000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13292000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-153122000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-47124000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-202000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	116000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1383000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-71670000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-13090000	USD
	us-gaap	Profit Loss ProfitLoss	-153238000	USD
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6800000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4700000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77670000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12790000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-160038000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50441000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99554000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93303000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	96659000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89452000	shares
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-71670000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-13090000	USD
	us-gaap	Profit Loss ProfitLoss	-153238000	USD
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1721000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-282000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2512000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1055000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	191000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	47000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	239000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	137000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1530000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-235000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2751000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79200000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13025000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-157287000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49249000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1192000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-73200000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13325000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-150487000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44549000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	6000000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-300000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	6800000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	4700000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1114589000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3851000	USD
CY2020Q3	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2020Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2247000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55198000	USD
CY2020Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-6000000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1530000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-71670000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1092204000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	815474000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4265000	USD
CY2019Q3	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	13000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3185000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5484000	USD
CY2019Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	300000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-235000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-13090000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	815396000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	798393000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1130000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7399000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	39000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3956000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2247000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	87351000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-6800000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2751000	USD
	us-gaap	Profit Loss ProfitLoss	-153238000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1092204000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	723000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349709000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9795000	USD
	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	82000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5118000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11882000	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	0	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	0	USD
	gh	Unrealized Translations Gain Loss On Obligation Related To Royalty UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty	330000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-4700000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1192000	USD
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	815396000	USD
	us-gaap	Profit Loss ProfitLoss	-153238000	USD
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11462000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7963000	USD
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	3349000	USD
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	2865000	USD
	gh	Charge Of In Process Research And Development ChargeOfInProcessResearchAndDevelopment	8500000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-120000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	87351000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11628000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17886000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2568000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-319401000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11882000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1636000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1953000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1235000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8056000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11581000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-908000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12550000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5624000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-491000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	453000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7571000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1043000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	846000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	426000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-340928000	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	228000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	125000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	79000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7399000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9795000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3956000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5118000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5480000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	11618000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1514000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6368000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3523000	USD
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	600000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4940000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3043000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44704000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16792000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	580172000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	542468000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	307548000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	223064000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7328000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28891000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2247000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	355730000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	350432000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1130000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	811000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	363583000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	364227000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	239000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-283000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143228000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142945000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147188000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10463000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9701000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4301000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6418000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1065000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations, goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, </span></div>including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The extent to which the COVID-19 pandemic will ultimately impact the Company’s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company’s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div>The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance.The Company is also subject to credit risk from its other receivables and other assets. The Company's other receivables and other assets include payments due from a third-party in relation to the settlement of a patent dispute reached during the three months ended September 30, 2020 for $8.0 million payable over a period of 6 years. The Company has evaluated and recorded a credit loss for the full amount considering the third-party's credit worthiness and lack of collection history.
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss ContractualReceivablesBeforeAllowanceForCreditLoss	8000000.0	USD
	gh	Contractual Receivables Term ContractualReceivablesTerm	P6Y
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	1000000	USD
CY2019Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	0	USD
CY2019Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	USD
CY2020Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	USD
	gh	Contractual Receivables Credit Loss Expense Reversal Current ContractualReceivablesCreditLossExpenseReversalCurrent	1000000	USD
CY2020Q3	gh	Contractual Receivables Credit Loss Expense Reversal Current ContractualReceivablesCreditLossExpenseReversalCurrent	1000000	USD
CY2020Q3	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1000000	USD
CY2020Q3	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1000000	USD
CY2020Q3	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	USD
CY2019Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	USD
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	7000000	USD
CY2019Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	0	USD
CY2020Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	0	USD
CY2019Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	0	USD
	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	7000000	USD
CY2020Q3	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	7000000	USD
CY2020Q3	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	USD
CY2020Q3	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	USD
CY2020Q3	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	USD
CY2019Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	11400000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	10900000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	21900000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	15500000	USD
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
	gh	Contract With Customer Liability Cumulative Catch Up Adjustment To Prior Year Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress	-3500000	USD
CY2020Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	13400000	USD
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	6200000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7300000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12300000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8800000	USD
	gh	Variable Interest Entity Threshold Percentageof Fair Valuethatis No Less Than Internal Rateof Return VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn	0.20
	gh	Variable Interest Entity Fair Value Of Joint Venture Threshold For Share Purchase VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase	0.40
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	61882000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43668000	USD
	us-gaap	Depreciation Depreciation	6800000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	93237000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	65591000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31355000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21923000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	3800000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	2500000	USD
	us-gaap	Depreciation Depreciation	10000000.0	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7438000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7140000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3751000	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3050000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2475000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3464000	USD
CY2020Q3	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	2489000	USD
CY2019Q4	gh	Accrued Clinical Trialsand Studies AccruedClinicalTrialsandStudies	2029000	USD
CY2020Q3	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	1808000	USD
CY2019Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	1046000	USD
CY2020Q3	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	668000	USD
CY2019Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	2424000	USD
CY2020Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	321000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1564000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3362000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4986000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22312000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25703000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1941000	USD
CY2020Q3	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	936058000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3903000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q3	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	939961000	USD
CY2019Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	657696000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1434000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	USD
CY2019Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	659091000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15045000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	3290000	USD
CY2020Q3	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1941000	USD
CY2020Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	19935000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	7600000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	676000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6924000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3290000	USD
CY2019Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	12490000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	676000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11814000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	491000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1947000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1947000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1947000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1953000	USD
CY2020Q3	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	6760000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15045000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3300000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2900000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0817
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0777
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1049000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9759000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9886000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10547000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10792000	USD
CY2020Q3	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	18350000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	60383000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13263000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	47120000	USD
CY2020Q3	gh	Lessee Operating Lease Lease Not Yet Commenced Weighted Average Term Of Contract LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract	P10Y
CY2017Q4	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	patent
CY2018Q3	us-gaap	Gain Contingency Patents Allegedly Infringed Upon Number GainContingencyPatentsAllegedlyInfringedUponNumber	4	patent
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2019	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	84.00
CY2020Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8277673	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8407162	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4312500	shares
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	354600000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5175000	shares
CY2019Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	71.00
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	349700000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2726225	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4494889	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.90
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
	us-gaap	Profit Loss ProfitLoss	-45741000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	306392000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	114472	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	114472	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	78.15
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1188519	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.23
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	17387	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64068	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.09
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2397256	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3356774	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.89
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	325246000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1826533	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	190313000	USD
	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Annual Increase In Shares Available SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	49.73
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	55.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	53.02
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	21000000.0	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55198000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5484000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	87351000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11882000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-71670000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-13090000	USD
	us-gaap	Profit Loss ProfitLoss	-153238000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6000000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6800000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	4700000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-77670000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12790000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-160038000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50441000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99554000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93303000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	96659000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89452000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7758000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5761000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6220000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6664000	shares
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1200000	USD
CY2020Q3	us-gaap	Revenues Revenues	74569000	USD
CY2019Q3	us-gaap	Revenues Revenues	60848000	USD
	us-gaap	Revenues Revenues	208414000	USD
	us-gaap	Revenues Revenues	151478000	USD

Files In Submission

Name	View Source	Status
0001628280-20-015769-index-headers.html	Edgar Link	pending
0001628280-20-015769-index.html	Edgar Link	pending
0001628280-20-015769.txt	Edgar Link	pending
0001628280-20-015769-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-0930x2020x10qxex311.htm	Edgar Link	pending
gh-0930x2020x10qxex312.htm	Edgar Link	pending
gh-0930x2020x10qxex321.htm	Edgar Link	pending
gh-0930x2020x10qxex322.htm	Edgar Link	pending
gh-20200930.htm	Edgar Link	pending
gh-20200930.xsd	Edgar Link	pending
gh-20200930_cal.xml	Edgar Link	unprocessable
gh-20200930_def.xml	Edgar Link	unprocessable
gh-20200930_htm.xml	Edgar Link	completed
gh-20200930_lab.xml	Edgar Link	unprocessable
gh-20200930_pre.xml	Edgar Link	unprocessable
gh-leasex0731x2020.htm	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_11.jpg	Edgar Link	pending
image_21.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
image_41.jpg	Edgar Link	pending
image_51.jpg	Edgar Link	pending
image_61.jpg	Edgar Link	pending
image_71.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2020 Q4 Form 10-Q Financial Statement

#000162828020015769 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2020 Q4 Form 10-Q Financial Statement

#000162828020015769 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh